moneyheap
FTRE · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Fortrea Holdings Inc. Common Stock (FTRE) stock moving?
Fortrea beat Q3 2026 estimates on October 29, with adjusted EPS of $0.28 against $0.22 expected and sales of $691.5M against $669.95M, and it lifted the low end of its FY2026 sales guidance to $2.665B-$2.690B. Book-to-bill was 1.12x. Five brokers then raised price targets within days: Truist to $29, Evercore to $28, Citigroup to $27, and Barclays and TD Cowen to $26, all with buy-equivalent ratings. Despite this, the stock fell about 10.6% on October 29, from $25.88 to $23.14, on roughly 4.95M shares, several times the typical daily volume in the window. It fell further to $21.29 on October 30 and touched a low of $19.66 on November 3. It has since recovered to $21.96 on November 6 and $22.24 on November 9, then closed at $21.39 on November 10, still about 17% below the October 28 close. The sell-off after a beat-and-raise and the rebound since then are not explained by the news provided, so the reason for the market's negative first reaction is unclear. The gap between the $21.39 close and the $26-$29 target range is wide, but the targets are analyst estimates and not a forecast.
News behind the analysis
- Fortrea Reports Third Quarter 2026 Financial ResultsFortrea reported Q3 2026 revenue of $691.5 million and a book-to-bill ratio of 1.12x for the quarter ended September 30, 2026.
- Fortrea Holdings Q3 Adj. EPS $0.28 Beats $0.22 Estimate, Sales $691.500M Beat $669.951M EstimateAdjusted EPS of $0.28 beat the $0.22 consensus, and sales of $691.5M beat the $669.95M estimate.
- Fortrea Holdings Raises FY2026 Sales Guidance from $2.620B-$2.690B to $2.665B-$2.690B vs $2.663B EstFortrea narrowed its FY2026 sales guidance to $2.665B-$2.690B, lifting the low end of the range above the $2.663B estimate.
- Fortrea Holdings Q3 2026 Earnings Call TranscriptBenzinga published the full transcript of Fortrea's Q3 2026 earnings call, held after the October 29 results release.
- Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $29Truist kept its Buy rating and raised its price target from $26 to $29.
- Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $27Citigroup kept its Buy rating and set a $27 price target on Fortrea.
- Evercore ISI Group Maintains Outperform on Fortrea Holdings, Raises Price Target to $28Evercore ISI kept its Outperform rating and raised its price target to $28.
- Barclays Maintains Overweight on Fortrea Holdings, Raises Price Target to $26Barclays kept its Overweight rating and raised its price target to $26.
- TD Cowen Maintains Buy on Fortrea Holdings, Raises Price Target to $26TD Cowen kept its Buy rating and raised its price target from $23 to $26.
About Fortrea Holdings Inc. Common Stock
Fortrea is a global contract research organization that runs clinical trials and related drug-development services for pharmaceutical, biotech and medical device companies. Labcorp spun it off in 2023, and it has been working through a turnaround focused on cutting costs, rebuilding its order book and using AI tools to work more efficiently.
How it makes money
It earns fees for running clinical trials for drug and device makers. That covers early-phase clinical pharmacology units (about 570+ beds after it bought Worldwide Clinical Trials' early-phase business in 2026), full-service Phase II–IV studies, and functional service provider (FSP) staffing contracts with large pharma companies. Reported revenue also includes pass-through costs, such as payments to trial sites, that it bills back to clients. Revenue for 2026 is guided at roughly $2.7 billion, and the company has a contract backlog of about $7.3 billion.
What usually moves FTRE
- Biotech funding and big-pharma R&D spending
- New business wins and book-to-bill ratio
- Contract cancellations and backlog conversion
- Progress on margins and the cost-cutting restructuring
- Debt levels and cash flow